- Home
- TKNO vs PLX Comparison
TKNO vs PLX Comparison
Compare TKNO & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TKNO | PLX |
|---|---|---|
| Founded | 1996 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 138.1M | 159.5M |
| IPO Year | 2021 | 1996 |
Fundamental Metrics
Financial Performance| Metric | TKNO | PLX |
|---|---|---|
| Price | $4.60 | $1.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 148.2K | ★ 825.2K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.86 | N/A |
| EPS | N/A | ★ 0.22 |
| Revenue | $40,520,000.00 | ★ $52,744,000.00 |
| Revenue This Year | $8.27 | $36.81 |
| Revenue Next Year | $13.13 | N/A |
| P/E Ratio | ★ N/A | $9.14 |
| Revenue Growth | ★ 7.35 | N/A |
| 52 Week Low | $1.91 | $1.34 |
| 52 Week High | $6.68 | $3.19 |
Technical Indicators
Market Signals| Indicator | TKNO | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 56.69 | 43.49 |
| Support Level | $3.64 | $1.87 |
| Resistance Level | $4.94 | $2.17 |
| Average True Range (ATR) | 0.51 | 0.08 |
| MACD | 0.07 | 0.00 |
| Stochastic Oscillator | 49.36 | 36.07 |
Price Performance
Historical ComparisonAbout TKNO Alpha Teknova Inc.
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its offer three product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It derives key revenue from United States.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.